Veradermics, Inc (MANE) Profit Breakdown
- 2026-06-30: Reportable -$23.50M.
- 2025-06-30: Reportable -$15.64M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2024-12-31 to 2026-06-30
- Data captured
Profit by product
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | -$23.50M |
|---|
| 2025-06-30 | -$15.64M |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|
| Indivior Pharmaceuticals, Inc. (INDV) | | $4.250B | 14.09 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|